#125049
Re: Farmas USA
NVAX
-
5,500 volunteers enrolled to date in pivotal Phase 3 clinical trial in the U.K.
- Study expanded to 15,000 participants
- Full enrollment expected by end of November
- Event-driven interim data expected as soon as early first quarter 2021
-
U.S. pivotal Phase 3 clinical trial planned to begin by end of November
- Significant progress in large-scale manufacturing achieved with some delay from original timeline
- Company to present data from its ongoing Phase 1/2 clinical trial, including new Phase 2 reactogenicity data, during public CDC Advisory Committee on Immunization Practices (ACIP) meeting on October 30